Combination Products Offer Regulatory Option For Novel Switches
This article was originally published in The Tan Sheet
Executive Summary
A novel switch application comprising a drug and a device would be “a classic combination product” and FDA has a framework for evaluation, says Bradley Merrill Thompson, an attorney who focuses on medical device law.
You may also be interested in...
Califf Supports Changing Combo Product Pathway; FDA Developing Proposal
FDA concepts for a new pathway could be ready for congressional scrutiny within a year, commissioner nominee Robert Califf says during his confirmation hearing.
Califf Supports Changing Combo Product Pathway; FDA Developing Proposal
FDA concepts for a new pathway could be ready for congressional scrutiny within a year, commissioner nominee Robert Califf says during his confirmation hearing.
FDA Taking Steps To Simplify Combo Product Consultations
The agency releases an internal assessment of how it handles inter-center consultations for combination products. As expected, there are some serious challenges to collaboration between the centers, but FDA says it is taking tangible steps to make it better.